Charles Riv­er’s CD­MO rev­enue rise; Catal­ent lays off 300 staffers; Bio­gen’s idle ca­pac­i­ty

Charles Riv­er’s over­all man­u­fac­tur­ing busi­ness saw a 9.5% de­crease in rev­enue in the last quar­ter of 2023 with $191.9 mil­lion, ver­sus $212.1 mil­lion in the same quar­ter the year pri­or. Its 2023 rev­enue al­so de­creased to $721.1 mil­lion, down from 2022’s $789.6 mil­lion.

But the com­pa­ny is still op­ti­mistic for its man­u­fac­tur­ing busi­ness, which is made up of its CD­MO, mi­cro­bial so­lu­tions and bi­o­log­ics test­ing seg­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER